HUE065578T2 - Kinazolin-származékok, mint daganatellenes szerek - Google Patents
Kinazolin-származékok, mint daganatellenes szerekInfo
- Publication number
- HUE065578T2 HUE065578T2 HUE19862146A HUE19862146A HUE065578T2 HU E065578 T2 HUE065578 T2 HU E065578T2 HU E19862146 A HUE19862146 A HU E19862146A HU E19862146 A HUE19862146 A HU E19862146A HU E065578 T2 HUE065578 T2 HU E065578T2
- Authority
- HU
- Hungary
- Prior art keywords
- antitumor agents
- quinazoline derivatives
- quinazoline
- derivatives
- antitumor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018106098 | 2018-09-18 | ||
| CN2019091078 | 2019-06-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE065578T2 true HUE065578T2 (hu) | 2024-06-28 |
Family
ID=69888359
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE19862146A HUE065578T2 (hu) | 2018-09-18 | 2019-09-17 | Kinazolin-származékok, mint daganatellenes szerek |
| HUE23219357A HUE069764T2 (hu) | 2018-09-18 | 2019-09-17 | Kinazolin-származékok, mint daganatellenes szerek |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE23219357A HUE069764T2 (hu) | 2018-09-18 | 2019-09-17 | Kinazolin-származékok, mint daganatellenes szerek |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US11723908B2 (OSRAM) |
| EP (3) | EP4360713B1 (OSRAM) |
| JP (3) | JP7546550B2 (OSRAM) |
| KR (2) | KR102889933B1 (OSRAM) |
| CN (2) | CN112654612A (OSRAM) |
| AU (2) | AU2019341273B2 (OSRAM) |
| CA (1) | CA3099776A1 (OSRAM) |
| DK (2) | DK4360713T3 (OSRAM) |
| ES (2) | ES2971927T3 (OSRAM) |
| FI (2) | FI3853220T3 (OSRAM) |
| HR (2) | HRP20240293T1 (OSRAM) |
| HU (2) | HUE065578T2 (OSRAM) |
| LT (2) | LT4360713T (OSRAM) |
| PL (2) | PL4360713T3 (OSRAM) |
| PT (2) | PT4360713T (OSRAM) |
| RS (2) | RS66314B1 (OSRAM) |
| SI (2) | SI3853220T1 (OSRAM) |
| SM (1) | SMT202400524T1 (OSRAM) |
| WO (1) | WO2020057511A1 (OSRAM) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019196622A1 (zh) * | 2018-04-09 | 2019-10-17 | 威尚（上海）生物医药有限公司 | 具有穿过血脑屏障能力的5取代二氟哌啶化合物 |
| CN110357858B (zh) | 2018-04-09 | 2022-02-18 | 威尚（上海）生物医药有限公司 | 具有穿过血脑屏障能力的5取代二氟哌啶化合物 |
| HUE065578T2 (hu) * | 2018-09-18 | 2024-06-28 | Hoffmann La Roche | Kinazolin-származékok, mint daganatellenes szerek |
| CN111377850B (zh) * | 2018-12-31 | 2022-10-18 | 艾琪康医药科技（上海）有限公司 | 一种手性n-取代-3,3-二氟-4-羟基哌啶衍生物及其制备方法 |
| TWI820414B (zh) * | 2020-04-17 | 2023-11-01 | 大陸商北京賽特明強醫藥科技有限公司 | 喹唑啉類化合物、製備方法及其應用 |
| CN113527215B (zh) * | 2020-04-17 | 2023-12-05 | 北京赛特明强医药科技有限公司 | 一种喹唑啉类化合物、制备方法及其应用 |
| TW202214641A (zh) | 2020-06-30 | 2022-04-16 | 美商艾瑞生藥股份有限公司 | Ｈｅｒ２突變抑制劑 |
| KR20230156767A (ko) * | 2021-03-19 | 2023-11-14 | 베이징 사이텍-엠큐 파마슈티컬즈 리미티드 | 퀴나졸린계 화합물, 조성물 및 퀴나졸린계 화합물의 적용 |
| CA3213079A1 (en) | 2021-04-13 | 2022-10-20 | Kristin Lynne ANDREWS | Amino-substituted heterocycles for treating cancers with egfr mutations |
| CN117858872A (zh) * | 2021-06-22 | 2024-04-09 | 缆图药品公司 | 用于治疗癌症的杂环egfr抑制剂 |
| WO2022271749A1 (en) * | 2021-06-22 | 2022-12-29 | Blueprint Medicines Corporation | Heterocyclic egfr inhibitors for use in the treatment of cancer |
| CN117940424A (zh) * | 2021-06-22 | 2024-04-26 | 缆图药品公司 | Egfr抑制剂 |
| CN117836286A (zh) * | 2021-06-22 | 2024-04-05 | 缆图药品公司 | 用于治疗癌症的杂环egfr抑制剂 |
| CN115894383B (zh) * | 2021-09-30 | 2025-12-19 | 北京赛特明强医药科技有限公司 | 一种喹唑啉类化合物、组合物及其应用 |
| CN115894455B (zh) * | 2021-09-30 | 2024-04-19 | 北京赛特明强医药科技有限公司 | 一种喹唑啉类化合物、组合物及其应用 |
| MA66471B1 (fr) * | 2021-10-20 | 2026-02-27 | F. Hoffmann-La Roche Ag | Formes cristallines de dérivés de quinazoline, leur préparation, leur composition et leur utilisation |
| WO2023138675A1 (zh) * | 2022-01-21 | 2023-07-27 | 默达药物（香港）有限公司 | 喹啉化合物及其用途 |
| US20230293539A1 (en) * | 2022-03-14 | 2023-09-21 | Huyabio International, Llc | Mll1-wdr5 protein-protein interaction inhibitor compounds and uses thereof |
| JP2025509995A (ja) * | 2022-03-28 | 2025-04-11 | 江蘇恒瑞医薬股▲ふん▼有限公司 | 含窒素複素環系化合物、その調製方法及びその医薬的使用 |
| CN115650977A (zh) * | 2022-10-09 | 2023-01-31 | 广东润兴生物科技有限公司 | 一种妥卡替尼的合成方法 |
| TW202446386A (zh) * | 2023-04-14 | 2024-12-01 | 大陸商迪哲（江蘇）醫藥股份有限公司 | 喹唑啉ＥｒｂＢ抑制劑的藥物形式 |
| WO2024249642A1 (en) * | 2023-06-02 | 2024-12-05 | Acerand Therapeutics (Hong Kong) Limited | Egfr inhibitors |
| AU2024353411A1 (en) * | 2023-09-27 | 2026-05-07 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Pharmaceutically acceptable salt and crystalline form of quinazoline derivative, and use thereof |
| WO2025195333A1 (en) | 2024-03-19 | 2025-09-25 | F. Hoffmann-La Roche Ag | Pharmaceutical formulation of erbb2 inhibitors |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0171407B1 (en) | 1984-01-30 | 1993-11-18 | Imperial Cancer Research Technology Limited | Improvements relating to growth factors |
| US5401638A (en) | 1986-06-04 | 1995-03-28 | Oncogene Science, Inc. | Detection and quantification of neu related proteins in the biological fluids of humans |
| US6743782B1 (en) | 1987-10-28 | 2004-06-01 | Wellstat Therapeutics Corporation | Acyl deoxyribonucleoside derivatives and uses thereof |
| EP0494135B1 (en) | 1989-09-29 | 1996-04-10 | Oncogene Science, Inc. | Human "neu" related protein p100 and use of the same for detecting preneoplastic or neoplastic cells in a human |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| WO1997030035A1 (en) | 1996-02-13 | 1997-08-21 | Zeneca Limited | Quinazoline derivatives as vegf inhibitors |
| ES2169355T3 (es) | 1996-03-05 | 2002-07-01 | Astrazeneca Ab | Derivados de 4-anilinoquinazolina. |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| US5994071A (en) | 1997-04-04 | 1999-11-30 | Albany Medical College | Assessment of prostate cancer |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| IL152682A0 (en) | 2000-05-31 | 2003-06-24 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
| NZ522568A (en) | 2000-06-22 | 2004-12-24 | Pfizer Prod Inc | Substituted bicyclic derivatives for the treatment of abnormal cell growth |
| BR0112224A (pt) | 2000-07-07 | 2003-06-10 | Angiogene Pharm Ltd | Composto, composição farmacêutica, uso de um composto ou de um sal, solvato ou pró-droga farmaceuticamente aceitável do mesmo, e, processo para preparar um composto |
| HUP0301742A3 (en) | 2000-07-07 | 2005-08-29 | Angiogene Pharm Ltd | Colchinol derivatives as angiogenesis inhibitors, process for producing them, pharmaceutical compositions containing them and their use |
| JP2005515176A (ja) | 2001-11-03 | 2005-05-26 | アストラゼネカ アクチボラグ | 抗腫瘍剤としてのキナゾリン誘導体 |
| US7235537B2 (en) | 2002-03-13 | 2007-06-26 | Array Biopharma, Inc. | N3 alkylated benzimidazole derivatives as MEK inhibitors |
| WO2004000529A1 (de) | 2002-06-24 | 2003-12-31 | Fagerdala Deutschland Gmbh | Verfahren zur herstellung von bauteilen aus hochgradig lignocellulosefaser-gefüllten thermoplasten |
| US7135575B2 (en) | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| JP4828421B2 (ja) | 2003-08-14 | 2011-11-30 | アレイ バイオファーマ、インコーポレイテッド | 受容体チロシンキナーゼ阻害剤としてのキナゾリン誘導体 |
| CA2755268C (en) * | 2005-11-15 | 2013-12-31 | Array Biopharma, Inc. | Erbb inhibitors |
| BRPI0720169A2 (pt) | 2006-12-12 | 2013-12-24 | Takeda Pharmaceutical | Composto ou um sal do mesmo, prodroga, agente farmacêutico, método para a profilaxia ou tratamento de câncer, e, uso do composto |
| WO2017148391A1 (zh) * | 2016-03-01 | 2017-09-08 | 上海医药集团股份有限公司 | 一种含氮杂环化合物、制备方法、中间体、组合物和应用 |
| EP3516071B1 (en) | 2016-09-22 | 2021-02-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of lung cancer |
| CN109422755B (zh) * | 2017-09-01 | 2023-07-04 | 上海医药集团股份有限公司 | 一种含氮杂环化合物、制备方法、中间体、组合物和应用 |
| WO2019120213A1 (zh) | 2017-12-19 | 2019-06-27 | 南京明德新药研发股份有限公司 | 喹唑啉衍生物及其应用 |
| US12030897B2 (en) | 2018-05-08 | 2024-07-09 | Medshine Discovery Inc. | Pyrrolo[2,1-f][1,2,4]triazine derivatives serving as selective HER2 inhibitors and application thereof |
| AR117424A1 (es) * | 2018-05-08 | 2021-08-04 | Dizal Jiangsu Pharmaceutical Co Ltd | Inhibidores de los receptores erbb |
| HUE065578T2 (hu) * | 2018-09-18 | 2024-06-28 | Hoffmann La Roche | Kinazolin-származékok, mint daganatellenes szerek |
-
2019
- 2019-09-17 HU HUE19862146A patent/HUE065578T2/hu unknown
- 2019-09-17 US US17/051,176 patent/US11723908B2/en active Active
- 2019-09-17 PT PT232193573T patent/PT4360713T/pt unknown
- 2019-09-17 PL PL23219357.3T patent/PL4360713T3/pl unknown
- 2019-09-17 KR KR1020217003251A patent/KR102889933B1/ko active Active
- 2019-09-17 FI FIEP19862146.8T patent/FI3853220T3/fi active
- 2019-09-17 ES ES19862146T patent/ES2971927T3/es active Active
- 2019-09-17 HR HRP20240293TT patent/HRP20240293T1/hr unknown
- 2019-09-17 DK DK23219357.3T patent/DK4360713T3/da active
- 2019-09-17 CN CN201980044137.8A patent/CN112654612A/zh active Pending
- 2019-09-17 RS RS20241396A patent/RS66314B1/sr unknown
- 2019-09-17 PT PT198621468T patent/PT3853220T/pt unknown
- 2019-09-17 KR KR1020257038595A patent/KR20250171398A/ko active Pending
- 2019-09-17 EP EP23219357.3A patent/EP4360713B1/en active Active
- 2019-09-17 HU HUE23219357A patent/HUE069764T2/hu unknown
- 2019-09-17 AU AU2019341273A patent/AU2019341273B2/en active Active
- 2019-09-17 SM SM20240524T patent/SMT202400524T1/it unknown
- 2019-09-17 HR HRP20241743TT patent/HRP20241743T1/hr unknown
- 2019-09-17 ES ES23219357T patent/ES3007082T3/es active Active
- 2019-09-17 LT LTEP23219357.3T patent/LT4360713T/lt unknown
- 2019-09-17 CN CN202410230537.0A patent/CN118255772A/zh active Pending
- 2019-09-17 FI FIEP23219357.3T patent/FI4360713T3/fi active
- 2019-09-17 LT LTEPPCT/CN2019/106233T patent/LT3853220T/lt unknown
- 2019-09-17 EP EP24208940.7A patent/EP4523755A3/en active Pending
- 2019-09-17 RS RS20240267A patent/RS65413B1/sr unknown
- 2019-09-17 SI SI201930718T patent/SI3853220T1/sl unknown
- 2019-09-17 EP EP19862146.8A patent/EP3853220B1/en active Active
- 2019-09-17 JP JP2021514381A patent/JP7546550B2/ja active Active
- 2019-09-17 DK DK19862146.8T patent/DK3853220T3/da active
- 2019-09-17 PL PL19862146.8T patent/PL3853220T3/pl unknown
- 2019-09-17 CA CA3099776A patent/CA3099776A1/en active Pending
- 2019-09-17 SI SI201930872T patent/SI4360713T1/sl unknown
- 2019-09-17 WO PCT/CN2019/106233 patent/WO2020057511A1/en not_active Ceased
-
2023
- 2023-05-18 US US18/319,509 patent/US20230293533A1/en active Pending
-
2024
- 2024-07-15 AU AU2024204847A patent/AU2024204847A1/en active Pending
- 2024-07-26 JP JP2024120830A patent/JP2024164018A/ja not_active Withdrawn
-
2025
- 2025-09-11 JP JP2025150799A patent/JP2026009898A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI4360713T1 (sl) | Derivati kinazolina kot protitumorska sredstva | |
| IL282167A (en) | Metabolized carbonucleosides and their use for cancer treatment | |
| IL268190A (en) | Quinazoline compound | |
| PL3642202T3 (pl) | Pochodne dihydropirolopirydyny | |
| IL253588B (en) | History of bicyclic quinazolinones | |
| HUE070924T2 (hu) | 2-Hidroxicikloalkán-1-karbamoil-származékok | |
| IL290815A (en) | History of alpha-d-galactopyranoside | |
| PL4077334T3 (pl) | Pochodne furoindazolu | |
| IL272652A (en) | A pentacyclic compound | |
| SG11202012594RA (en) | Spirochromane derivatives | |
| LT3796975T (lt) | Sulfonilaminobenzamido dariniai | |
| IL261201A (en) | Derivatives of aminobenzimidazole | |
| GB201919210D0 (en) | Dihydro-cyclopenta-isoquinoline derivatives | |
| PL3770162T3 (pl) | Pochodne dihydrochromenu | |
| EP3624805A4 (en) | PYRAZOLOCHINAZOLINONE ANTITUMOR AGENTS | |
| ZA202200181B (en) | 2-hydroxycycloalkane-1-carbamoyl derivatives | |
| HK40027177A (en) | Pyrazoloquinazolinone antitumor agents | |
| GB201806948D0 (en) | Derivatives |